| centanafadine SR (EB-1020) / Otsuka |
NCT02547428: Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 2b | 85 | US | CTN SR, Centanafadine Sustained-Release, Matching placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Attention Deficit Disorder With Hyperactivity | 06/16 | 06/16 | | |
NCT04081363: Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 2a | 13 | US | Centanafadine, EB-1020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Attention Deficit Hyperactivity Disorder | 12/19 | 12/19 | | |
NCT01939353: Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder |
|
|
| Completed | 2 | 45 | US | CTN SR, EB-1020 SR, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Adult ADHD | 02/14 | 02/14 | | |
NCT05066724: Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment |
|
|
| Completed | 2 | 50 | US | Centanafadine | Otsuka Pharmaceutical Development & Commercialization, Inc. | Smoking Cessation | 05/22 | 05/22 | | |
NCT05113953: A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder |
|
|
| Completed | 2 | 147 | US | Centanafadine, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Binge-Eating Disorder | 08/22 | 08/22 | | |
JUNIPER, NCT05536414: Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder |
|
|
| Recruiting | 2 | 336 | US | Centanafadine, Escitalopram, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder | 01/25 | 01/25 | | |
